#USA #FieldForce™ #Ventricular Tachycardia #Cardiff-by-the-Sea #Field Medical

New Breakthrough in Cardiac Care: Field Medical's FieldForce™ System

Field Medical, Inc. has made significant strides in the medical field with the announcement of promising results from their innovative FieldForce™ Pulsed Field Ablation System. Recently published in Circulation and presented at the 20th Annual International Symposium on Ventricular Arrhythmias, this research marks a pivotal moment for patients suffering from ventricular tachycardia (VT).

A New Approach to VT Treatment

The Ventricular Catheter Ablation Study (VCAS) is a groundbreaking prospective trial aimed at assessing the safety and effectiveness of the FieldForce™ system in individuals experiencing VT. This patient-friendly approach incorporates a unique technique that utilizes high-voltage, short-pulse waveforms. Unlike traditional methods that risk damaging surrounding tissues, this system aims to penetrate dense scar tissues, thereby minimizing thermal injury.

Key Findings from the Six-Month Outcomes

Efficacy in Reducing Recurrence

The results have been nothing short of astounding. In the six-month follow-up:

• - 82% of patients experienced freedom from recurrent VT and ventricular fibrillation (VF) therapy.
• - A staggering 98% reduction in the burden of VT and VF episodes was recorded.
• - Only 11.5% of participants encountered primary safety events, with no complications related to the therapy itself.

Dr. Vivek Reddy, a key investigator and electrophysiologist at Mount Sinai in New York, expressed his optimism about the results, stating, "This is the first evidence we've encountered that pulsed field ablation can effectively reach deep scar tissue in the ventricle." He emphasized that achieving such successful outcomes is a hopeful indication for the future of VT treatment.

The Road Ahead

Though the study remains in its early feasibility stages, the outcomes signal a promising advancement in treating scar-related VT. The system has earned the prestigious FDA Breakthrough Device designation, a status designed to expedite the development of medical devices that offer significant improvements over existing therapies.

Dr. Steven Mickelsen, the founder and CTO of Field Medical, commented on the significance of these findings: "It's uncommon for initial feasibility data to be published in such a notable journal as Circulation., highlighting the impact and rigor of this research. Our goal has always been to meld scientific credibility with innovative technology."

Looking ahead, Field Medical aims to explore broader applications for the FieldForce™ system beyond VT treatments, with the hope of presenting positive results from atrial fibrillation assessments at a major scientific meeting in 2026.

Conclusion

This launch signals a new era in the treatment of ventricular arrhythmias. With advanced technology that fosters a deep understanding of cardiac conditions and encourages innovative solutions, Field Medical offers hope to many who face this challenging health issue. For more information about their pioneering technology, visit Field Medical’s official website.

The FieldForce™ Ablation System remains an investigational device, restricted to research use under federal law. Its exceptional findings highlight not only the potential for improved patient outcomes but also the collaborative effort necessary to advance medical technology.